China Sets Ambitious Biomedical Goals At Binhai
Smart technology applications have gradually been applied to help facilitate the upgrading and modernization of production and manufacturing
The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem cells.
The annual business revenue of the biomedical industry in Binhai is expected to reach 100 billion yuan ($15.44 billion) by 2025 with the companies as the major driving force.
Located on the eastern coast of Tianjin, Binhai is an important area for the development of both the Bohai Economic Rim and Beijing-Tianjin-Hebei region.
The new area is developing into a new frontier for biomedical research. It has gathered leading players in the field, such as Novo Nordisk, the world's largest producer of insulin, and Tianjin International Joint Academy of Biomedicine, introducing global high-end talents to boost research.
In 2020, Binhai 's biomedical industry output value stood at 40.25 billion yuan, accounting for 64.2 percent of the city's total biomedical output.
By 2025, Binhai will have been shaped into a highly innovative and internationally competitive drug development and manufacturing piloting zone, characterized by its comprehensive subdivisions and variety of complete medical products.